Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Impact of Adaptive Clinical Trial
Design on Market Authorization
and Reimbursement
Kristian Thorlund, PhD, MSc
2
Intro teaser
Ebola outbreak has
now affected
millions in Africa
(since early 2014)
Discussions on best
clinical trials d...
3
Intro teaser
Mar ’14: Investigate
Multiple Exp Tx
Aug ‘14: Parallel RCTs,
adaptive too complex
Oct ‘14: Adaptive ideal
…...
Conclusion
4
Actions speak louder that words
Find a way to utilize innovative designs
and study them in the process
Don’t ...
Background
5
HTA decision-making is built on the conventional
EBM paradigm putting large parallel design RCTs
at the top o...
Background
The commercial clinical trials space has changed
considerably over the past decade
• Increased focus on sub-pop...
Background
These changes has brought about a focus on
efficient and innovative trials that do not lend
themselves to conve...
8
Increasingly complex designs
(innovative designs)
Kieseier BC et al. Mult. Scler 2014 [Epub ahead of print]
9Sandborn WJ et al Gastroenterol 2014; 146(1):96-109.
Increasingly complex designs
(innovative designs)
10Feagan BG et al. NEJM 2013; 369:8
Innovative
designs
Mismatches with HTA
• Commercial innovative trials typically lack
long-term ‘pure’ placebo/control data or
sufficient plac...
Misunderstandings in HTA
• No long-term comparative estimates equals
mean no long-term cost-effectiveness equals
no reimbu...
What can we do?
13
Educate & Innovate!
What can we do?
14
… and apply!
Conclusion (reiterated)
15
Actions speak louder that words
Find a way to utilize innovative designs
and study them in the ...
16
Thank you!
Upcoming SlideShare
Loading in …5
×

Cadth 2015 e4 thorlund innovative trial designs in medical decision making

382 views

Published on

CADTH 2015 Symposium

Published in: Health & Medicine
  • Be the first to comment

Cadth 2015 e4 thorlund innovative trial designs in medical decision making

  1. 1. Impact of Adaptive Clinical Trial Design on Market Authorization and Reimbursement Kristian Thorlund, PhD, MSc
  2. 2. 2 Intro teaser Ebola outbreak has now affected millions in Africa (since early 2014) Discussions on best clinical trials design still ongoing
  3. 3. 3 Intro teaser Mar ’14: Investigate Multiple Exp Tx Aug ‘14: Parallel RCTs, adaptive too complex Oct ‘14: Adaptive ideal … MSF/Welcome Trust pro no control FDA/NIH pro control
  4. 4. Conclusion 4 Actions speak louder that words Find a way to utilize innovative designs and study them in the process Don’t just wait for them to be validated
  5. 5. Background 5 HTA decision-making is built on the conventional EBM paradigm putting large parallel design RCTs at the top of the evidence hierarchy
  6. 6. Background The commercial clinical trials space has changed considerably over the past decade • Increased focus on sub-populations • Increased demand for trial patients • Absence of equipoise in commercial trials • Needs for fast evidence 6
  7. 7. Background These changes has brought about a focus on efficient and innovative trials that do not lend themselves to conventional decision-making 7
  8. 8. 8 Increasingly complex designs (innovative designs) Kieseier BC et al. Mult. Scler 2014 [Epub ahead of print]
  9. 9. 9Sandborn WJ et al Gastroenterol 2014; 146(1):96-109. Increasingly complex designs (innovative designs)
  10. 10. 10Feagan BG et al. NEJM 2013; 369:8 Innovative designs
  11. 11. Mismatches with HTA • Commercial innovative trials typically lack long-term ‘pure’ placebo/control data or sufficient placebo/control data • Experimental Tx data may not resemble approved Tx algorithms due to the dynamic nature of innovative trials 11
  12. 12. Misunderstandings in HTA • No long-term comparative estimates equals mean no long-term cost-effectiveness equals no reimbursement decision (or a rejection) • Sparse control data equals ‘p>0.05’ and therefore no difference 12
  13. 13. What can we do? 13 Educate & Innovate!
  14. 14. What can we do? 14 … and apply!
  15. 15. Conclusion (reiterated) 15 Actions speak louder that words Find a way to utilize innovative designs and study them in the process Don’t just wait for them to be validated
  16. 16. 16 Thank you!

×